– Program provides accessible and affordable testing for pediatric epilepsy patients – – Genetic and clinical insights from test results to strengthen Invitae's rare disease database – SAN FRANCISCO , July 22 , 2024 /PRNewswire/ -- Invitae (OTC: NVTAQ), a leading medical genetics company, today announced the launch of its UnlockTM Behind the Seizure ® program, which provides accessible and affordable genetic testing for pediatric epilepsy patients in the hopes of shortening the diagnostic odyssey and enabling a path towards effective, personalized care and precision therapy 1 . Millions of people worldwide live with epilepsy and more than half of epilepsies are caused by genetic abnormalities. Clinical practice guidelines recommend genetic testing for all patients with otherwise unexplained epilepsy 2 , in part because early genetic testing can provide a direct, cost-effective and accurate tool to help support a diagnosis, and is associated with fewer invasive procedures for patients.
3 Invitae Unlock Behind the Seizure is designed to make testing for patients under the age of 18 more accessible and affordable by assisting patients. Invitae believes that with results from this program, healthcare providers may gain insights into the underlying genetic cause of their patients' epilepsy, which can inform tailored treatment plans. In a study, Invitae found that among patients with epilepsy and a molecular diagnosis, those tested with Invitae's epilepsy panel had a 1.
4-f.